In Vitro Activities of Moxifloxacin and Other Fluoroquinolones against Mycoplasma pneumoniae

Abstract

A total of 105 isolates of Mycoplasma pneumoniae were evaluated for susceptibility to moxifloxacin, sparfloxacin, levofloxacin, and ciprofloxacin. Moxifloxacin, a newly synthesized compound, showed the greatest activity. The MICs and MBCs at which 50 and 90% of isolates were affected were 0.15 (MIC 50 and MBC 50 ) and 0.3 g/ml (MIC 90 and MBC 90 ) respectively. The results indicate that moxifloxacin might be promising an antimycoplasmal agent.Mycoplasma pneumoniae is the causative agent of upper respiratory tract infections and pneumonia in humans (6). Recently the efficacy of new quinolones has been demonstrated in vitro against various respiratory pathogens, including M. pneumoniae (2,4,11). In this report, we compared the in vitro activity of moxifloxacin, a new member of the fluoroquinolone group which has potent antimicrobial activities against grampositive and gram-negative bacteria (3, 9), with those of other fluoroquinolone as references against M. pneumoniae.A total of 105 strains of M. pneumoniae isolated from throat swabs from patients with pneumonia from 1986 (and earlier) to 2000 were used. These strains were subcultured fewer than five times in liquid medium and stored at Ϫ80°C until use. The antimicrobial agents used were moxifloxacin (Bay12-8039; Bayer Yakuhin Ltd.), sparfloxacin (SPFX; Dainippon Pharmaceutical Co., Ltd.) levofloxacin (LVFX; Daiichi Pharmaceutical Co., Ltd.), and ciprofloxacin (CPFX; Bayer Yakuhin Ltd.). The MICs and MBCs against each drug were determined by serial dilutions of the drugs in broth medium as described previously (5,8). Briefly, each strain of M. pneumoniae cultured for 5 days was diluted to 10 5 CFU/ml and 200 l of each sample was cultured in a sealed microtiter plate (Nunc Co., Ltd., Roskilde, Denmark) at 37°C. After 2 days of cultivation, twofold dilutions of the antimicrobial agents were added to samples of each strain. After an additional 2 days of cultivation, two and three 10-fold dilutions of each sample were used for plating on agar plates to provide a range of 500 to 1,000 CFU/10 l of the sample. The number of mycoplasmas in broth without drugs reached approximately 10 7 CFU/ml. MIC is defined as the lowest concentration of an antimcrobial agent inhibiting more than 99% of the mycoplasmal colonies with the control. The definition of MBC most often used in clinical microbiology is the lowest drug concentration that kills 99.9% of the bacterial population in a liquid medium.As shown in Fig. 1a, moxifloxacin (MIC for 50% of isolates [MIC 50 ], 0.15 g/ml; MIC for 90% of isolates [MIC 90 ], 0.3 g/ml) was more active than SPFX (MIC 50 , 0.3 g/ml; MIC 90 , 1.25 g/ml), LVFX (MIC 50 , 1.25 g/ml; MIC 90 , 2.5 g/ml), and CPFX (MIC 50 , 5.0 g/ml, MIC 90 , 5.0 g/ml). The MBCs and their distributions among the strains for these agents are shown in Fig. 1b; the MBCs of moxifloxacin (MBC 50 , 0.15 g/ml; MBC 90 , 0.3 g/ml) were markedly lower than those of SPFX (MBC 50 , 0.6 g/ml; MBC 90 , 2.5 g/ml), LVFX (MBC 50 , 2.5 g/ml; MBC 90 , 5.0 g/ml), and CPFX (MBC 50 , 5.0 g/m...

ComparativeIn Vitro Susceptibilities and Bactericidal Activities ofInvestigational Fluoroquinolone ABT-492 and Other Antimicrobial Agentsagainst Human Mycoplasmas andUreaplasmas

“…MIC and MBC data for ciprofloxacin, levofloxacin, moxifloxacin, and gatifloxacin are consistent with previously published results for these drugs tested against human mycoplasmas and ureaplasmas (1)(2)(3)(4)(5)(6)(7)(8)(9). The results of this study support the future clinical development of ABT-492 as a potential treatment for diseases caused by these organisms.…”

Antibiotic Susceptibility Testing of Mycoplasma genitalium by TaqMan 5′ Nuclease Real-Time PCR

“…However, the MICs for MXF of these two strains were 0.125 mg/liter and 0.25 mg/liter, respectively, and thus this newer fluoroquinolone with an extended gram-positive spectrum would be expected to be clinically effective. The potent antimicrobial activity of MXF has also been reported for M. pneumoniae, (12), and recently, clinical reports showing that MXF was effective in recurrent or MO-401, 2005). This is in good agreement with our clinical observations, which have shown a good microbiological and clinical cure rate after MXF treatment in persistent or recurring urethritis.…”

Mycoplasma pneumonia: Clinical features and management

“…describe a real-time based PCR and high resolution melt analysis for rapid detection of macrolide resistant strain in M. pneumoniae . Fluoroquinolones[ 72 ] may show anti mycoplasmal activities against macrolide and tetracycline resistant strains of M. pneumoniae because of their mechanism of action and their excellent penetration into lung tissue, in particular bronchial secretions.…”